Astria Therapeutics (ATXS, $9) was a top loser over the last three months, falling -1 to $9 per share. A.I.dvisor analyzed 913 stocks in the Biotechnology Industry for the 3-month period ending April 26, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.